MA52691A - STATIN COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES - Google Patents
STATIN COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIESInfo
- Publication number
- MA52691A MA52691A MA052691A MA52691A MA52691A MA 52691 A MA52691 A MA 52691A MA 052691 A MA052691 A MA 052691A MA 52691 A MA52691 A MA 52691A MA 52691 A MA52691 A MA 52691A
- Authority
- MA
- Morocco
- Prior art keywords
- synucleinopathies
- treatment
- methods
- statin compositions
- statin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762528204P | 2017-07-03 | 2017-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52691A true MA52691A (en) | 2021-03-31 |
Family
ID=64950317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052691A MA52691A (en) | 2017-07-03 | 2018-07-03 | STATIN COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200113899A1 (en) |
| EP (1) | EP3648756A4 (en) |
| JP (1) | JP2020526487A (en) |
| KR (1) | KR20200026925A (en) |
| CN (1) | CN111093647A (en) |
| AU (1) | AU2018298012A1 (en) |
| BR (1) | BR112020000021A2 (en) |
| CA (1) | CA3105337A1 (en) |
| EA (1) | EA202090194A1 (en) |
| IL (1) | IL271758A (en) |
| MA (1) | MA52691A (en) |
| MX (1) | MX2019015280A (en) |
| TW (1) | TW201906605A (en) |
| WO (1) | WO2019010146A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12502370B2 (en) * | 2019-04-11 | 2025-12-23 | Cmpd Licensing, Llc | Wound treatments and compositions |
| US11793783B2 (en) | 2015-08-05 | 2023-10-24 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11446236B2 (en) | 2015-08-05 | 2022-09-20 | Cmpd Licensing, Llc | Topical antimicrobial compositions and methods of formulating the same |
| US11684567B2 (en) | 2015-08-05 | 2023-06-27 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US12156875B2 (en) | 2019-04-11 | 2024-12-03 | Cmpd Licensing, Llc | Wound treatments and compositions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009109990A2 (en) * | 2008-01-24 | 2009-09-11 | Sun Pharmaceutical Industries Ltd. | Pharmaceutical composition of pramipexole |
| WO2010010136A1 (en) * | 2008-07-24 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising pramipexole and an anti-inflammatory agent for the treatment of parkinson's disease |
| JP2016528276A (en) * | 2013-08-21 | 2016-09-15 | レスバーロジックス コーポレイション | Composition and therapy for promoting plaque regression |
-
2018
- 2018-07-03 JP JP2019571571A patent/JP2020526487A/en active Pending
- 2018-07-03 EA EA202090194A patent/EA202090194A1/en unknown
- 2018-07-03 KR KR1020207003016A patent/KR20200026925A/en not_active Ceased
- 2018-07-03 MA MA052691A patent/MA52691A/en unknown
- 2018-07-03 EP EP18827639.8A patent/EP3648756A4/en not_active Withdrawn
- 2018-07-03 TW TW107123009A patent/TW201906605A/en unknown
- 2018-07-03 MX MX2019015280A patent/MX2019015280A/en unknown
- 2018-07-03 US US16/613,013 patent/US20200113899A1/en not_active Abandoned
- 2018-07-03 AU AU2018298012A patent/AU2018298012A1/en not_active Abandoned
- 2018-07-03 WO PCT/US2018/040665 patent/WO2019010146A1/en not_active Ceased
- 2018-07-03 CN CN201880044738.4A patent/CN111093647A/en active Pending
- 2018-07-03 BR BR112020000021-3A patent/BR112020000021A2/en not_active IP Right Cessation
- 2018-07-03 CA CA3105337A patent/CA3105337A1/en active Pending
-
2019
- 2019-12-30 IL IL271758A patent/IL271758A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA202090194A1 (en) | 2020-05-27 |
| MX2019015280A (en) | 2020-08-17 |
| EP3648756A1 (en) | 2020-05-13 |
| TW201906605A (en) | 2019-02-16 |
| WO2019010146A1 (en) | 2019-01-10 |
| BR112020000021A2 (en) | 2020-07-21 |
| US20200113899A1 (en) | 2020-04-16 |
| IL271758A (en) | 2020-02-27 |
| CA3105337A1 (en) | 2019-01-10 |
| EP3648756A4 (en) | 2021-03-31 |
| CN111093647A (en) | 2020-05-01 |
| AU2018298012A1 (en) | 2020-02-13 |
| KR20200026925A (en) | 2020-03-11 |
| JP2020526487A (en) | 2020-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3377042A4 (en) | SUBSTANCES AND METHODS FOR THE TREATMENT OF MYOPATHIES BASED ON TITINE AND OTHER TITINOPATHIES | |
| EP3645739A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
| MA45290A (en) | PROCESSES AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | |
| EP3704239A4 (en) | CASZ COMPOSITIONS AND METHODS OF USE | |
| MA45270A (en) | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES | |
| EP3630072A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF EXCESSIVE DROWSINESS | |
| FR24C1010I2 (en) | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | |
| EP3634430A4 (en) | MULTIBIOTIC AGENTS AND METHODS OF USE THEREOF | |
| MA52691A (en) | STATIN COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | |
| EP3474879A4 (en) | COMPOSITIONS AND METHODS FOR TREATING MELANOMA | |
| MA47688A (en) | USEFUL COMPOSITIONS IN THE TREATMENT OF SPINAL AMYOTROPHY | |
| EP3612215A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY INFLAMMATION | |
| MA71705A (en) | SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | |
| MA45688A (en) | COMPOSITIONS AND METHODS FOR THE POTENTIALIZATION OF ANTIMICROBIAL AGENTS | |
| MA50849A (en) | SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | |
| EP3341391A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN | |
| MA46427A (en) | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES | |
| EP3735325A4 (en) | SURFACE TREATMENT COMPOSITIONS AND METHODS | |
| EP3390642A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PIGMENT RETINITY 18 AND PIGMENT RETINITY 13 | |
| MA53873A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | |
| EP3833340A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYTIA | |
| MA55821A (en) | 5-HT2A ANTAGONISTS FOR USE IN THE TREATMENT OF DEPRESSION | |
| EP3448421A4 (en) | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SURGICAL ADHESIONS | |
| MA49248A (en) | FGFR2 INHIBITORS USED IN THE TREATMENT OF CHOLANGIOCARCINOMA | |
| EP3645120A4 (en) | NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF DEPRESSION |